Citations

Clear

371 citation(s) found for "Cho, B".

Effect of Intensive Blood Pressure Reduction on Left Ventricular Mass, Structure, Function, and Fibrosis in the SPRINT-HEART
Upadhya, Bharathi , Rocco, Michael V. , Morgan, Tim, Blackshear, Joseph L., Hundley, William Greg, Oparil, Suzanne , Soliman, Elsayed Z. , Cohen, Debbie L. , Hamilton, Craig A. , Cho, Monique E. , Kostis, William J. , Raj, Dominic S. , Townsend, Ray, Vasu, Sujethra, Zamanian, Sara, Kitzman, Dalane W. , Hundley, W. Gregory , Blackshear, Joseph, Rocco, Michael V , Pajewski, Nicholas M. , Papademetriou, Vasilios , Rodríguez, Carlos J. , Zamanian, Sara

Mayo Clinic

Hypertension | July 1, 2019 | Volume: 74 | Issue: 2 | Pages: 276-284

10.1161/hypertensionaha.119.13073 | PMID 31256724 Get It

In observational studies, left ventricular mass (LVM) and structure are strong predictors of mortality and cardiovascular events. However, the effect of hypertension treatment on LVM reduction and its relation to subsequent outcomes is unclear, particularly at lower blood pressure (BP) targets. In an ancillary study of SPRINT (Systolic Blood Pressure Intervention Trial), where participants were randomly assigned to intensive BP control (target systolic BP target <120 mm Hg) versus standard BP control (<140 mm Hg), cardiac magnetic resonance imaging was performed at baseline and 18-month follow-up to measure: LVM, volumes, ejection fraction, and native T1 mapping for myocardial fibrosis. At baseline, 337 participants were examined (age: 64±9 years, 45% women); 300 completed the 18-month exam (153 intensive control and 147 standard control). In the intensive versus standard BP control group at 18 months, there was no difference in change in LVM (mean±SE =−2.7±0.5 g versus −2.3±0.7 g; P =0.368), ejection fraction, or native T1 ( P =0.79), but there was a larger decrease in LVM/end-diastolic volume ratio (−0.04±0.01 versus −0.01±0.01; P =0.002) a measure of concentric LV remodeling. There were fewer cardiovascular events in the intensive control group, but no significant association between the reduced events and change in LVM or any other cardiac magnetic resonance imaging measure. In SPRINT-HEART, contrary to our hypothesis, there were no significant between-group differences in LVM, function, or myocardial T1 at 18-month follow-up. These results suggests that mediators other than these LV measures contribute to the improved cardiovascular outcomes with intensive BP control.
An Implementation Guide to Promote Sleep and Reduce Sedative-Hypnotic Initiation for Noncritically Ill Inpatients
Cho, Hyung J. , Gathecha, Evelyn , Kisuule, Flora, Tannenbaum, Cara , Vijenthira, Abi , Morgenthaler, Timothy, Soong, Christine , Burry, Lisa , Morgenthaler, Timothy I.

Mayo Clinic

JAMA Internal Medicine | June 3, 2019 | Volume: 179 | Issue: 7 | Pages: 965

10.1001/jamainternmed.2019.1196 | PMID 31157831 Get It

Cost-effectiveness (CE) of regorafenib dose optimization schedule in metastatic colorectal cancer.
Hay, Joel W. , Lenz, Heinz‐Josef , Barzi, Afsaneh , Cho, Sang Kyu , Ou, Fang‐Shu , Grothey, Axel , Bekaii‐Saab, Tanios

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: e18367-e18367

10.1200/jco.2019.37.15_suppl.e18367 Get It

e18367 Background: Regorafenib at 160mg daily 21/28 days is a standard therapeutic option in patients with metastatic colorectal cancer. However, the cost of treatment and management of its side-effects is more than the cost-effectiveness threshold for oncology drugs in US and many countries around the world. ReDOS (Regorafenib Dose Optimization Study), is a randomized phase II trial in refractory mCRC and established that weekly dose escalation of regorafenib over the conventional dosing is superior in the composite endpoint of safety and efficacy. We explored the impact of the new dosing strategy on CE of regorafenib. Methods: A Markov model was constructed to compare costs and effectiveness of regorafenib (standard), regorafenib (ReDOS), and best supportive care (BSC). Model inputs for clinical efficacy and safety were from the CORRECT trial for regorafenib (standard) and BSC, and the ReDOS study for regorafenib (ReDOS). The incremental cost-effectiveness ratios (ICERs) were reported to compare treatments. Model robustness was checked with univariate and probabilistic sensitivity analyses. The model used a US payer’s perspective with 5% annual discount rate, and all costs were measured in 2018 US dollars. Results: Regorafenib (ReDOS) dominated regorafenib (standard), producing higher quality-adjusted life years at a lower cost. When compared to BSC, regorafenib (ReDOS) resulted in the ICER of $112,705 while regorafenib (standard) resulted in the ICER of $384,687. The most influential parameters on the ICERs were efficacy and health state utility parameters under univariate sensitivity analysis. In probabilistic sensitivity analysis using cost-effectiveness acceptability curves, regorafenib (ReDOS) was more cost-effective than regorafenib (standard) and BSC in 70% of repetition at the willingness-to-pay threshold of $120,000 per QALY (Quality-Adjusted Life Year) and 98% at a WTP threshold of $150,000. Conclusions: Based on the outcomes demonstrated in the ReDOS study, the dose optimization strategy of regorafenib results in favorable cost-effectiveness under a typical US willingness-to-pay threshold of $150,000 per QALY.
Abstract LB-242: Aberrant crypt foci (ACF) are not surrogate biomarkers of sporadic adenoma prevention with celecoxib: Results from the Adenoma Prevention with Celecoxib (APC) trial
Cho, Nancy L. , Redston, Mark , Carothers, Adelaide M., Wilton, Andrew S. , Sontag, Stephen J. , Nishioka, Norman S., Giardiello, Frances, Saltzman, John R. , Gostout, Chris, Eagle, Craig, Hawk, Ernest T. , Zauber, Ann Graham , Hornick, Jason L. , Bertagnolli, Monica M.

Mayo Clinic

Cancer Research | May 11, 2019 | Volume: 68 | Issue: 9_Supplement | Pages: LB-242-LB-242

10.1158/1538-7445.am2008-lb-242 Get It

Abstract Aberrant crypt foci (ACF) are the earliest visible neoplastic lesions in the colorectum. The natural history of these lesions and their role in the adenoma-carcinoma sequence are unknown. We studied ACF in a subset of patients enrolled in the Adenoma Prevention with Celecoxib (APC) Trial to determine whether the presence of ACF in the rectum correlated with that of adenomas in the entire large intestine. Participants were randomized to placebo (n=17), celecoxib 200 mg bid (n=15), or celecoxib 400 mg bid (n=13). Magnification chromoendoscopy (MCE) was performed to identify and biopsy ACF within the rectum at baseline and after 8-12 months of medication use. A total of 670 ACF were identified in 45 patients, and 70 of these were examined histologically. All of the ACF examined were non-dysplastic. Analysis showed no differences in ACF number between baseline and post-treatment studies (8.3±1.0 vs. 6.3±1.1) and no modulation by treatment (celecoxib vs placebo; p=0.77). Immunohistochemical studies showed that ACF contained cells exhibiting increased proliferation, but lacked other features of neoplasia such as increased Cox-2 expression and microvascular density, nuclear localization of β-catenin, or decreased expression of the tumor suppressors SMAD4, estrogen receptor (ERα) or MGMT. Of the secondary markers assessed at baseline, only SMAD4 expression correlated with post-treatment adenoma recurrence. Taken together, these data showed that non-dysplastic ACF are not accurate surrogate endpoint biomarkers of colorectal adenoma risk or NSAID chemoprevention response.
90-day Readmission in Elective Primary Lumbar Spine Surgery in the Inpatient Setting
Rubel, Nicholas , Chung, Andrew S. , Wong, Michael S. , Lara, Nina , Makovicka, Justin L. , Cho, Samuel , Chang, Michael S., Cho, Samuel K. , Rubel, Nicolas C, Wong, Michael, Lara, Nina J, Chung, Andrew , Wong, Michael, Chang, Michael S.

Mayo Clinic

Spine | March 3, 2019 | Volume: 44 | Issue: 14 | Pages: E857-E864

10.1097/brs.0000000000002995 | PMID 30817732 Get It

Study Design. Secondary analysis of a large administrative database. Objective. The objectives of this study are to: 1) identify the incidence and cause of 90-day readmissions following primary elective lumbar spine surgery, 2) offer insight into potential risk factors that contribute to these readmissions, and 3) quantify the cost associated with these readmissions. Summary of Background Data. As bundled-payment models for the reimbursement of surgical services become more popular in spine, the focus is shifting toward long-term patient outcomes in the context of 90-day episodes of care. With limited data available on national 90-day readmission statistics available, we hope to provide evidence that will aid in the development of more cost-effective perioperative care models. Methods. Using ICD-9 coding, we identified all patients 18 years of age and older in the 2014 Nationwide Readmissions Database (NRD) who underwent an elective, inpatient, primary lumbar spine surgery. Using multivariate logistic regression, we identified independent predictors of 90-day readmission while controlling for a multitude of confounding variables and completed a comparative cost analysis. Results. We identified 169,788 patients who underwent a primary lumbar spine procedure. In total 4268 (2.5%) were readmitted within 90 days. There was no difference in comorbidity burden between cohorts (readmitted vs. not readmitted) as quantified by the Elixhauser Comorbidity index. Independent predictors of increased odds of 90-day readmission were: anemia, uncomplicated diabetes and diabetes with chronic complications, surgical wound disruption and acute myocardial infarction at the time of the index admission, self-pay status, and an anterior surgical approach. Implant complications were identified as the primary related cause of readmission. These readmissions were associated with a significant cost increase. Conclusion. There are clearly identifiable risk factors that increase the odds of hospital readmission within 90 days of primary lumbar spine surgery. An overall 90-day readmission rate of 2.5%, while relatively low, carries significantly increased cost to both the patient and hospital. Level of Evidence: 3
Recommendations on the Use of Ultrasound Guidance for Adult Abdominal Paracentesis: A Position Statement of the Society of Hospital Medicine
Cho, Joel, Jensen, Trevor, Reierson, Kreegan , Mathews, Benji K., Bhagra, Anjali , Franco‐Sadud, Ricardo, Grikis, Loretta, Mader, Michael , Dancel, Ria , Lucas, Brian , Soni, Nilam J. , Tierney, David M. , Arntfield, Robert , Soni, Nilam J

Mayo Clinic

Journal of Hospital Medicine | February 26, 2019 | Volume: 14 | Issue: 1 | Pages: No page available

10.12788/jhm.3095 | PMID 30604780 Get It

EXECUTIVE SUMMARY We recommend that ultrasound guidance should be used for paracentesis to reduce the risk of serious complications, the most common being bleeding. We recommend that ultrasound guidance should be used to avoid attempting paracentesis in patients with an insufficient volume of intraperitoneal free fluid to drain. We recommend that ultrasound guidance should be used with paracentesis to improve the success rates of the overall procedure. We recommend that ultrasound should be used to assess the volume and location of intraperitoneal free fluid to guide clinical decision making of where paracentesis can be safely performed. We recommend that ultrasound should be used to identify a needle insertion site based on size of the fluid collection, thickness of the abdominal wall, and proximity to abdominal organs. We recommend that the needle insertion site should be evaluated using color flow Doppler ultrasound to identify and avoid abdominal wall blood vessels along the anticipated needle trajectory. We recommend that a needle insertion site should be evaluated in multiple planes to ensure clearance from underlying abdominal organs and detect any abdominal wall blood vessels along the anticipated needle trajectory. We recommend that a needle insertion site should be marked with ultrasound immediately before performing the procedure, and the patient should remain in the same position between marking the site and performing the procedure. We recommend that using real‐time ultrasound guidance for paracentesis should be considered when the fluid collection is small or difficult to access. We recommend that dedicated training sessions, including didactics, supervised practice on patients, and simulation‐based practice, should be used to teach novices how to perform ultrasound‐guided paracentesis. We recommend that simulation‐based practice should be used, when available, to facilitate acquisition of the required knowledge and skills to perform ultrasound‐ guided paracentesis. We recommend that competence in performing ultrasound‐guided paracentesis should be demonstrated prior to independently performing the procedure on patients.
Point‐of‐Care Ultrasound for Hospitalists: A Position Statement of the Society of Hospital Medicine
Soni, Nilam J. , Schnobrich, Daniel, Mathews, Benji K., Tierney, David M. , Jensen, Trevor, Dancel, Ria , Cho, Joel, Dversdal, Renee K. , Mints, G. E. , Bhagra, Anjali , Reierson, Kreegan , Kurian, Linda M. , Liu, Gigi , Candotti, Carolina, LoPresti, Charles M. , Wong, Tanping , Johnson, Gordon E., Maw, Anna , Franco‐Sadud, Ricardo, Lucas, Brian , Boesch, Brandon, Lenchus, Joshua D. , Soni, Nilam J

Mayo Clinic

Journal of Hospital Medicine | February 26, 2019 | Volume: 14 | Issue: 1 | Pages: No page available

10.12788/jhm.3079 | PMID 30604779 Get It

Many hospitalists incorporate point‐of‐care ultrasound (POCUS) into their daily practice to answer specific diagnostic questions or to guide performance of invasive bedside procedures. However, standards for hospitalists in POCUS training and assessment are not yet established. Most internal medicine residency training programs, the major pipeline for incoming hospitalists, have only recently begun to incorporate POCUS in their curricula. The purpose of this document is to inform a broad audience on what POCUS is and how hospitalists are using it. This document is intended to provide guidance for the hospitalists who use POCUS and administrators who oversee its use. We discuss POCUS 1) applications, 2) training, 3) assessments, and 4) program management. Practicing hospitalists must continue to collaborate with their local credentialing bodies to outline requirements for POCUS use. Hospitalists should be integrally involved in decision‐making processes surrounding POCUS program management.
Identifying patient‐important outcomes in polycystic kidney disease: An international nominal group technique study
Cho, Yeoungjee , Sautenet, Bénédicte , Gutman, Talia , Rangan, Gopala K. , Craig, Jonathan C. , Ong, Albert , Chapman, Arlene B., Coolican, Helen, Kao, Juliana T‐W, Gansevoort, Ron T. , Harris, Tess , Torres, Vicente E. , Pei, York , Ryan, Jessica , Johnson, David W. , Viecelli, Andrea K. , Geneste, Claire, Oh, Yun Kyu , Teixeira‐Pinto, Armando , Logeman, Charlotte , Howell, Martin , Ju, Angela, Manera, Karine , Tong, Allison , Torres, Vicente E , Johnson, David W , Howell, Martin , Ong, Albert C M , Ahn, Curie , Kao, Juliana Tze‐Wah , Perrone, Ronald D. , Kerr, Peter G. , Kim, Hyunsuk , Kim, Yaerim , Cho, Yeoungjee

Mayo Clinic

Nephrology | January 21, 2019 | Volume: 24 | Issue: 12 | Pages: 1214-1224

10.1111/nep.13566 | PMID 30663163 Get It

ABSTRACTAimPatients with autosomal dominant polycystic kidney disease (ADPKD) are at increased risk of premature mortality, morbidities and complications, which severely impair quality of life. However, patient‐centered outcomes are not consistently reported in trials in ADPKD, which can limit shared decision‐making. We aimed to identify outcomes important to patients and caregivers and the reasons for their priorities.MethodsNominal group technique was adopted involving patients with ADPKD and caregivers who were purposively selected from eight centres across Australia, France and the Republic of Korea. Participants identified, ranked and discussed outcomes for trials in ADPKD. We calculated an importance score (0–1) for each outcome and conducted thematic analyses.ResultsAcross 17 groups, 154 participants (121 patients, 33 caregivers) aged 19 to 78 (mean 54.5 years) identified 55 outcomes. The 10 highest ranked outcomes were: kidney function (importance score 0.36), end‐stage kidney disease (0.32), survival (0.21), cyst size/growth (0.20), cyst pain/bleeding (0.18), blood pressure (0.17), ability to work (0.16), cerebral aneurysm/stroke (0.14), mobility/physical function (0.12), and fatigue (0.12). Three themes were identified: threatening semblance of normality, inability to control and making sense of diverse risks.ConclusionFor patients with ADPKD and their caregivers, kidney function, delayed progression to end‐stage kidney disease and survival were the highest priorities, and were focused on achieving normality, and maintaining control over health and lifestyle. Implementing these patient‐important outcomes may improve the meaning and relevance of trials to inform clinical care in ADPKD.
Nearly complete deletion of BubR1 causes microcephaly through shortened mitosis and massive cell death
Simmons, Ambrosia , Park, Raehee, Sterling, Noelle A. , Jang, Mi‐Hyeon , Deursen, Jan M. A. van, Cho, Seo-Hee, van Deursen, Jan M A, Yen, Tim J. , Kim, Seonhee

Mayo Clinic

Human Molecular Genetics | January 18, 2019 | Volume: 28 | Issue: 11 | Pages: 1822-1836

10.1093/hmg/ddz022 | PMID 30668728 Get It

Abstract BUB-related 1 (BubR1) encoded by Budding Uninhibited by Benzimidazole 1B (BUB1B) is a crucial mitotic checkpoint protein ensuring proper segregation of chromosomes during mitosis. Mutations of BUB1B are responsible for mosaic variegated aneuploidy (MVA), a human congenital disorder characterized by extensive abnormalities in chromosome number. Although microcephaly is a prominent feature of MVA carrying the BUB1B mutation, how BubR1 deficiency disturbs neural progenitor proliferation and neuronal output and leads to microcephaly is unknown. Here we show that conditional loss of BubR1 in mouse cerebral cortex recapitulates microcephaly. BubR1-deficient cortex includes a strikingly reduced number of late-born, but not of early-born, neurons, although BubR1 expression is substantially reduced from an early stage. Importantly, absence of BubR1 decreases the proportion of neural progenitors in mitosis, specifically in metaphase, suggesting shortened mitosis owing to premature chromosome segregation. In the BubR1 mutant, massive apoptotic cell death, which is likely due to the compromised genomic integrity that results from aberrant mitosis, depletes progenitors and neurons during neurogenesis. There is no apparent alteration in centrosome number, spindle formation or primary cilia, suggesting that the major effect of BubR1 deficiency on neural progenitors is to impair the mitotic checkpoint. This finding highlights the importance of the mitotic checkpoint in the pathogenesis of microcephaly. Furthermore, the ependymal cell layer does not form in the conditional knockout, revealing an unrecognized role of BubR1 in assuring the integrity of the ventricular system, which may account for the presence of hydrocephalus in some patients.